The Trustees of Princeton University;Rutgers, The State University of New Jersey
发明人:
Robert K. PRUD'HOMME,Patrick J. SINKO,Howard A. STONE,Nathalie M. PINKERTON,Lei SHI,Jiandi WAN,Sherif IBRAHIM,Dayuan GAO,Robert K. PRUDHOMME
申请号：
US15243234
公开号：
US20170042818A1
申请日:
2016.08.22
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The American Cancer Society estimated that in 2009, 1,479,350 new cancer cases would be diagnosed in the United States of which 219,440 would be lung and bronchus related. The standard treatments for NSCLC include surgery, chemotherapy, radiation, laser and photodynamic therapy, all with various success rates depending on the stage of the cancer. National Cancer Institute assesses, however, that results of standard treatment are generally poor with only a 15 percent 5-year survival rate for combined cancer stages. Challenges facing the current chemotherapy drugs include excessive toxicity to healthy tissues and limited ability to prevent metastases. A dual drug delivery system described herein selectively targets the lung to deliver anti-cancer drugs and inhibit the formation of metastases.
